Zdravljenje bolnikov s ploščatoceličnim karcinomom glave in vratu z obsevanjem in cetuksimabom

Show document
A+ | A- | | SLO | ENG

Title:	Zdravljenje bolnikov s ploščatoceličnim karcinomom glave in vratu z obsevanjem in cetuksimabom
Authors:	ID Strojan, Primož (Author) ID Zakotnik, Branko (Author)
Files:	PDF - Presentation file, download (385,52 KB) MD5: 262B1576CA75AB08DF8374CF4554CEBE PID: 20.500.12556/dirros/e1e5dc5c-7260-46ee-9694-1703a5e04bce
Language:	Slovenian
Typology:	1.04 - Professional Article
Organization:	OI - Institute of Oncology
Publication status:	Published
Publication version:	Version of Record
Year of publishing:	2008
Number of pages:	str. 84-88
Numbering:	Letn. 12, št. 2
PID:	20.500.12556/DiRROS-9038
UDC:	616-006
ISSN on article:	1408-1741
URN:	URN:NBN:SI:doc-PMPB2DPT
COBISS.SI-ID:	701051
Copyright:	by Authors
Note:	BSDOCID143366;
Publication date in DiRROS:	31.08.2018
Views:	2903
Downloads:	651
Metadata:
:	Copy citation

Share:

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

License:	CC BY 4.0, Creative Commons Attribution 4.0 International

Link:	http://creativecommons.org/licenses/by/4.0/
Description:	This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:	31.08.2018

Language:	English
Title:	Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck with Concomitant Irradiation and Cetuximab
Abstract:	Contemporary management of locally and regionally advanced squamous cell carcinoma of the head and neck combines simultaneous application of radiotherapy and chemotherapy. With more comprehensive understanding of radiobiological principles of radiotherapy and recent developments in biological drug modeling and technology, more room was provided for improving some other areas of treatment. One of the new promising strategies in the treatment of head and neck carcinomas is the inhibition of epidermal growth factor receptor (EGFR) signaling using anti-EGFR monoclonal antibodies (e.g. cetuximab, Erbitux). In this article, we present the first two patients treated at the Institute of Oncology Ljubljana with the combination of irradiation and cetuximab and discuss theoretical background for the new treatment regime and other possible therapeutic indications for cetuximab in head and neck oncology.